Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle DiseaseNews DeskJune 11, 20260 A Novartis RNA therapy reduced blood levels of a protein that’s a biological indicator of a particular form of muscular…